Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.

MLA

Coleman, Robert L., et al. “Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.” The New England Journal of Medicine, vol. 381, no. 25, Dec. 2019, pp. 2403–15. EBSCOhost, https://doi.org/10.1056/NEJMoa1909707.

APA

Coleman, R. L., Fleming, G. F., Brady, M. F., Swisher, E. M., Steffensen, K. D., Friedlander, M., Okamoto, A., Moore, K. N., Efrat Ben-Baruch, N., Werner, T. L., Cloven, N. G., Oaknin, A., DiSilvestro, P. A., Morgan, M. A., Nam, J.-H., Leath, C. A., 3rd, Nicum, S., Hagemann, A. R., Littell, R. D., … Bookman, M. A. (2019). Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. The New England Journal of Medicine, 381(25), 2403–2415. https://doi.org/10.1056/NEJMoa1909707

Chicago

Coleman, Robert L, Gini F Fleming, Mark F Brady, Elizabeth M Swisher, Karina D Steffensen, Michael Friedlander, Aikou Okamoto, et al. 2019. “Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer.” The New England Journal of Medicine 381 (25): 2403–15. doi:10.1056/NEJMoa1909707.